Analabs Resources Berhad Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Analabs Resources Berhad şirketinin toplam hissedar öz sermayesi MYR468.4M ve toplam borcu MYR183.0M olup, bu da borç-öz sermaye oranını 39.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla MYR689.4M ve MYR221.0M dir. Analabs Resources Berhad 'in FAVÖK'ü MYR36.9M faiz karşılama oranı -295.5 dur. Şirketin MYR20.2M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

39.1%

Borç/özkaynak oranı

RM 183.03m

Borç

Faiz karşılama oranı	-295.5x
Nakit	RM 20.18m
Eşitlik	RM 468.44m
Toplam yükümlülükler	RM 220.96m
Toplam varlıklar	RM 689.40m

Son finansal sağlık güncellemeleri

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Jan 04

Analabs Resources Berhad (KLSE:ANALABS) Has A Pretty Healthy Balance Sheet

Jan 21

Here's Why Analabs Resources Berhad (KLSE:ANALABS) Can Manage Its Debt Responsibly

Sep 13

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

May 24

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Feb 09

Recent updates

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Jan 04

Analabs Resources Berhad (KLSE:ANALABS) Is Due To Pay A Dividend Of MYR0.02

Feb 13

Analabs Resources Berhad (KLSE:ANALABS) Is Doing The Right Things To Multiply Its Share Price

Mar 28

Analabs Resources Berhad (KLSE:ANALABS) Has A Pretty Healthy Balance Sheet

Jan 21

Here's Why Analabs Resources Berhad (KLSE:ANALABS) Can Manage Its Debt Responsibly

Sep 13

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

May 24

Analabs Resources Berhad (KLSE:ANALABS) Might Be Having Difficulty Using Its Capital Effectively

Apr 28

Here's Why We Think Analabs Resources Berhad (KLSE:ANALABS) Is Well Worth Watching

Apr 07

Could Analabs Resources Berhad (KLSE:ANALABS) Have The Makings Of Another Dividend Aristocrat?

Mar 17

Should You Buy Analabs Resources Berhad (KLSE:ANALABS) For Its Upcoming Dividend?

Feb 19

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ANALABS 'nin kısa vadeli varlıkları ( MYR69.5M ) kısa vadeli yükümlülüklerini ( MYR185.9M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: ANALABS şirketinin kısa vadeli varlıkları ( MYR69.5M ) uzun vadeli yükümlülüklerini ( MYR35.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ANALABS 'nin net borç/öz sermaye oranı ( 34.8% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: ANALABS şirketinin borç/öz sermaye oranı son 5 yılda 9.9% seviyesinden 39.1% seviyesine yükseldi.

Borç Kapsamı: ANALABS 'nin borcu işletme nakit akışı ( 12.4% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: ANALABS ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Analabs Resources Berhad Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Analabs Resources Berhad (KLSE:ANALABS) Has A Pretty Healthy Balance Sheet

Here's Why Analabs Resources Berhad (KLSE:ANALABS) Can Manage Its Debt Responsibly

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Recent updates

First quarter 2025 earnings released: EPS: RM0.051 (vs RM0.036 in 1Q 2024)

Analabs Resources Berhad, Annual General Meeting, Oct 10, 2024

Full year 2024 earnings released: EPS: RM0.25 (vs RM0.21 in FY 2023)

Third quarter 2024 earnings released: EPS: RM0.026 (vs RM0.012 in 3Q 2023)

Analabs Resources Berhad Appoints Ling Hua Kang as Independent and Non Executive Member of Remuneration Committee

Upcoming dividend of RM0.021 per share

Analabs Resources Berhad Declares an Single Tier Interim Dividend for the Financial Year Ending 30 April 2024, Payable on 22 March 2024

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

New major risk - Financial position

Analabs Resources Berhad Reports Write Offs for the Quarter Ended October 31, 2023

Analabs Resources Berhad Declares Interim Dividend for the Financial Year Ending 30 April 2024

Analabs Resources Berhad Appoints Mr. Ling Hua Kang as Independent and Non Executive Independent Director

Full year 2023 earnings released: EPS: RM0.21 (vs RM0.27 in FY 2022)

Analabs Resources Berhad, Annual General Meeting, Oct 04, 2023

Full year 2023 earnings released: EPS: RM0.21 (vs RM0.27 in FY 2022)

Third quarter 2023 earnings released: EPS: RM0.012 (vs RM0.098 in 3Q 2022)

Upcoming dividend of RM0.02 per share at 1.4% yield

Analabs Resources Berhad (KLSE:ANALABS) Is Due To Pay A Dividend Of MYR0.02

Analabs Resources Berhad Declares Interim Dividend for the Financial Year Ending 30 April 2023, Payable on 10 March 2023

Second quarter 2023 earnings released: EPS: RM0.051 (vs RM0.063 in 2Q 2022)

Analabs Resources Berhad Declares Single Tier Interim Dividend for the Financial Year Ending 30 April 2023

Analabs Resources Berhad Announces Cessation of Office of Mr. Lai Yew Choong as Independent and Non Executive Member of Risk Committee

Insufficient new directors

Analabs Resources Berhad, Annual General Meeting, Oct 05, 2022

Analabs Resources Berhad Appoints Chia Yee Yan as Independent and Non Executive Member of Audit Committee

Full year 2022 earnings released: EPS: RM0.27 (vs RM0.15 in FY 2021)

Analabs Resources Berhad Appoints Chia Yee Yan as Independent and Non Executive Director

Analabs Resources Berhad Re-Designates Kan Mun Hoow as Chief Executive Officer, Effective from 1 April 2022

Analabs Resources Berhad (KLSE:ANALABS) Is Doing The Right Things To Multiply Its Share Price

Third quarter 2022 earnings released: EPS: RM0.098 (vs RM0.051 in 3Q 2021)

Upcoming dividend of RM0.02 per share

Analabs Resources Berhad Announces Single-Tier Interim Dividend for the Period Ending April 30, 2022, Payable on March 11, 2022

Analabs Resources Berhad (KLSE:ANALABS) Has A Pretty Healthy Balance Sheet

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Here's Why Analabs Resources Berhad (KLSE:ANALABS) Can Manage Its Debt Responsibly

Full year 2021 earnings released: EPS RM0.15 (vs RM0.067 in FY 2020)

Full year 2021 earnings released

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Analabs Resources Berhad (KLSE:ANALABS) Might Be Having Difficulty Using Its Capital Effectively

Here's Why We Think Analabs Resources Berhad (KLSE:ANALABS) Is Well Worth Watching

Third quarter 2021 earnings released: EPS RM0.051 (vs RM0.012 in 3Q 2020)

Could Analabs Resources Berhad (KLSE:ANALABS) Have The Makings Of Another Dividend Aristocrat?

New 90-day low: RM1.10

Should You Buy Analabs Resources Berhad (KLSE:ANALABS) For Its Upcoming Dividend?

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

New 90-day high: RM1.19

Is Analabs Resources Berhad (KLSE:ANALABS) Set To Make A Turnaround?

Second quarter 2021 earnings released: EPS RM0.022

Is Analabs Resources Berhad (KLSE:ANALABS) An Attractive Dividend Stock?

New 90-day high: RM1.22

Analabs Resources Berhad Announces the Resignation of TAN AI PENG as Company Secretary

First quarter earnings released

Full year earnings released - EPS RM0.067

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin